Celltrion gets US FDA approval for new biosimilar for autoimmune disease treatment
Seoul, Jan 31 (IANS) Celltrion, a major South Korean biopharmaceutical firm, on Friday said its new biosimilar for an autoimmune disease treatment has received approval from the US Food and Drug Administration (FDA). The FDA approved Celltrion’s Avtozma, a biosimilar to Actemra, in both intravenous and subcutaneous formulations, according to the company, Yonhap news agency […]
